Paying celebrities to shill your drugs

Allergan’s Latisse is an eyelash-growing drug prescribed to treat a condition called hypotrichosis. This is a condition of no hair growth (not to be confused with the condition of alopecia, which describes hair loss where formerly there was hair growth).  That’s not how Allergan chose to describe the condition of hypotrichosis on its Latisse Patient Information sheet:

“Hypotrichosis is another name for having inadequate or not enough eyelashes.”

But as John Mack astutely notes in Pharma Marketing News:

“I imagine asking a woman if she has ‘adequate’ or ‘enough’ eyelashes is like asking a man if he has a ‘big’ enough or ‘hard’ enough penis. It is unlikely, therefore, that any woman wouldn’t want to try Latisse at least once.”

How then to get more women to ask more doctors to help sell more of this eyelash-growing drug?  Hire a famous person to pitch your product! Enter professional celebrity-for-hire (Volkswagen-Ford-Coppertone-LaZBoy-Colgate-Tupperware) Brooke Shields, who explains on her Latisse video diary how she also became a paid shill for this Allergan drug:      , Continue reading

Is ugliness a disease?

Something strange is happening in medicine, according to physician,  bioethicist and author Dr. Carl Elliott in his landmarkarticle in The Guardian called Is Ugliness a Disease?  No longer, he claims, is medicine being used merely to cure illness. Medicine is now being used in the pursuit of happiness. We take Viagra at bedtime and Ritalin before work. We inject Botox into our wrinkled brows and rub Rogaine on our balding heads. We swallow Paxil for shyness, Prozac for grief, and Buspar for anxiety.

“For stage fright we use beta blockers; for excessive blushing and sweating, we get endoscopic surgery. We ask surgeons to trim down our noses and suck fat from our thighs in the pursuit of what we believe to be our true selves.  Continue reading

Same old duet: drug companies and psychiatry

Here’s more this month from investigative journalist Alison Bass, author of the book Side Effects: A Prosecutor, a Whistleblower, and A Bestselling Antidepressant on Trial:

“The same drug giants paying millions of dollars to settle claims that they engaged in illegal and improper marketing of anti-psychotic drugs in the U.S. are even now looking for new worlds to conquer. Consider the study published in the Archives of General Psychiatry. It surveyed more than 60,000 adults in 11 countries in Eastern Europe, Asia and South America and concludes that the treatment needs for people with bipolar disorder are “often unmet, particularly in low-income countries.”

“That may indeed be true. But I’d find this result a lot more believable if the study were not funded in large part by the same pharmaceutical companies who make the atypical anti-psychotics used to treat bipolar disorder: Eli Lilly (which makes Zyprexa), Janssen (the unit of Johnson & Johnson that brought us Risperdal), Pfizer (Geodon), Bristol Myers Squibb (Abilify), GlaxoSmithKline (Lamictal), and Novartis (Fanapt).  Continue reading

Why you should take Zoloft – for everything!

The smarty-pants over at The Onion have come up with a few new uses for Pfizer’s blockbuster anti-depressant drug Zoloft while taking aim at those Direct-To-Consumer (“ask your doctor”) ads convincing consumers they need it. Even though this concept is a gag, it’s frighteningly close to the reality that Big Pharma is creeping towards.  Continue reading